Souhaitez-vous accéder aux communiqués récents ?

Canada Growth Fund, the Government of Québec, through Investissement Québec, and Eni S.p.A., commit to an aggregate US$213 million equity investment, to support the advancement of NMG’s Phase-2...

WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of...

Company positions itself to become a dedicated AI infrastructure partner for the financial technology and digital assets ecosystem, deploying secure, on-premises systems where proprietary trading...

Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief...

VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- EquityInsider.com Sector Commentary — Canada just committed over $3.6 billion to fast-track critical minerals projects at the world's...

Sparian Biosciences initiates a phase 1 clinical trial of SBS-147, its next generation arylepoxamide receptor (AEAr) agonist for acute and chronic pain.

Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles between the two dose groupsAzenosertib...

Lead candidate, CBT-001 for the treatment of pterygium, a multi-billion-dollar addressable market, is in mid-Phase 3 with initial topline data anticipated in Q3 2026 Second asset, CBT-004 for the...

Solengepras, a once-daily, oral, non-dopaminergic GPR6 inhibitor, demonstrated meaningful reductions in daily OFF time and improvements in sleep-related symptoms across two Phase 2 trialsMeeting...

EMERYVILLE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for...